The development of biosimilar products
continues to gain momentum across
the world. The path forward, however,
remains arduous, requiring protracted
dialogue between the industry and global
regulators. And nowhere was this more
apparent than at the 2017 PDA/FDA
Biosimilars Conference, June 26–27, 2017
in Bethesda, Md.